NewcelX Ltd. (NCEL): Total Liabilities
$4.20M
As of 2025-12-31
-11.2%
3-year compound annual growth
-16.3%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $4.20M | -52.9% | 2026-04-29, Balance as of period end |
| 2024-12-31 | $8.90M | -16.7% | 2026-04-29, Balance as of period end |
| 2023-12-31 | $10.68M | +78.1% | 2025-05-16, Balance as of period end |
| 2022-12-31 | $6.00M | +14.8% | 2024-05-15, Balance as of period end |
| 2021-12-31 | $5.22M | -48.8% | 2023-05-05, Balance as of period end |
| 2020-12-31 | $10.20M | +48.5% | 2022-03-24, Balance as of period end |
| 2019-12-31 | $6.87M | n/a | 2021-05-14, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| NewcelX Ltd. (NCEL) | 2025-12-31 | $4.20M | -52.9% |
| Curanex Pharmaceuticals Inc (CURX) | 2025-12-31 | $361.0K | n/m |
| Revelation Biosciences, Inc. (REVB) | 2025-12-31 | $2.72M | +42.2% |
| MetaVia Inc. (MTVA) | 2025-12-31 | $5.79M | -30.5% |
| Mira Pharmaceuticals, Inc. (MIRA) | 2025-12-31 | $702.1K | -2.9% |
| Decoy Therapeutics Inc. (DCOY) | 2025-12-31 | $5.17M | +241.9% |
| Lantern Pharma Inc. (LTRN) | 2025-12-31 | $4.50M | +2.7% |
| PRF Technologies Ltd. (PRFX) | 2025-12-31 | $2.71M | +0.3% |
| Anebulo Pharmaceuticals, Inc. (ANEB) | 2025-06-30 | $487.7K | +87.2% |
Compare NCEL, CURX, REVB, MTVA side by side · Screen every company in Pharmaceutical Preparations ↗